This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Abbott Splurges on Therasense

Abbott Laboratories (ABT - Get Report) agreed to acquire Therasense (THER - Get Report) for $27 a share in cash, or more than 100 times expected 2004 earnings for a company that makes blood-glucose test kits.

TheraSense, based in Alameda, Calif., makes and sells the FreeStyle blood glucose self-monitoring kit, and specializes in diabetes test systems that use small blood samples to produce rapid test results.

The $27 buyout price -- which comes out to $1.12 billion -- is a big premium to Therasense's Monday close of $20.30 and its 52-week high of $21.48. It's also more than five times the company's trailing 12-month revenue of about $196 million, although that revenue is growing at a roughly 150% rate. Therasense isn't currently profitable, but analysts expect it to earn 26 cents a share next year.

Therasense was recently up $6.40, or 31.5%, to $26.70 in Instinet premarket trading.

"Together with TheraSense, Abbott can build on its success in the blood glucose monitoring business," Abbott said in a release. "We will continue to promote both the MediSense and TheraSense products and brands. This transaction will allow us to better serve the needs of people with diabetes through advanced technology, a promising pipeline, a broader product line, and critical mass in research, development, sales and marketing."

Abbott expects the acquisition to dilute earnings by 1 cent a share in 2004 and turn accretive thereafter. It will also result in "one-time charges" in the second quarter, primarily for in-process research and development, and "throughout 2004 for integration expenses."

The transaction is also subject to approval by holders of a majority of TheraSense common stock at a special meeting of stockholders; regulatory approvals; and other closing conditions. The deal is expected to close in the second quarter of 2004.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
THER $0.52 0.00%
ABT $47.08 0.00%
AAPL $125.70 -0.53%
FB $82.85 -0.41%
GOOG $549.83 -0.40%

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs